Natera Validates Signatera for Lymphoma MRD Assessment
AUSTIN, Texas, September 1, 2026 Natera announced publication of new clinical data in Blood Neoplasia supporting the prognostic and...
ADC AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
AUSTIN, Texas, September 1, 2026 Natera announced publication of new clinical data in Blood Neoplasia supporting the prognostic and...
CARLSBAD, Calif., June 11, 2026 Arima Genomics, a cancer diagnostics company focused on integrating DNA sequence and genome structure...
South San Francisco, California | April 13, 2026 Allogene Therapeutics has announced encouraging interim results from its pivotal Phase...
